Introduction
Hepatocellular carcinoma (HCC) is the most frequent subtype of primary liver cancer with high lethality. 1 Recent statistical data demonstrated that the 5-year survival rate of HCC is still below 20%. 2, 3 One of reasons responsible for high mortality is the extrahepatic spread of primary tumor loci with partly elucidated mechanism. 4, 5 Till now, lung is considered as the most favored organ for HCC metastatic colonization, counting for 51% of all extrahepatic metastasis. 6 Result from a large-scale population study showed that the 1-year overall survival (OS) and cancer-specific survival (CSS) was 10% and 12.6% in patients diagnosed with HCC lung metastasis (HCCLM). 1 With the conceptual update in treatment modalities, new attempts, such as simultaneous hepatectomy and pulmonary metastasectomy, have been made by surgeons in selected individuals to achieve a better survival. [8] [9] [10] In addition, Yang et al elucidated that patients receiving combined treatment had a better survival by analyzing 76 consecutive HCC patients initially presenting with lung metastasis. 11 However, primary and secondary prevention strategies also played a pivotal role in cancer remedy. Early recognition of patients with high risk for development of HCCLM and subsequent surveillance should be proposed. A previous article illustrated that HCC <7 cm in diameter had higher risk of forming lung metastasis after primary liver cancer resection. 12 Due to a low prevalence of HCCLM, a large-scale population-based study is needed for systematic identification of the morbidity, potential risk factors, and clinical prognosis of initial HCCLM patients.
In the present research, we retrospectively reviewed data from the Surveillance, Epidemiology, and End Results (SEER) database to explore the actual incidence and identify factors contributing to initially diagnosed HCCLM. Furthermore, stratified survival estimates and variables affecting either OS or CSS recognition were also conducted.
Patients and methods

Data source and patient enrollment
Original data were retrieved from the SEER database maintained by the National Cancer Institute. The SEER program consists of 18 population-based cancer registries, covering ~28% of all population in the USA. The distant metastasis status were collected until 2010 due to the intrinsic reason of the database and the latest revision was released on April 16, 2018. The inclusion criteria were as follows: 1) primary site labeled as "C22.0 Liver" and ICD-O-3 histology/behavior marked with "8,170/3: hepatocellular carcinoma, not otherwise specified," "8,171/3: hepatocellular carcinoma, fibrolamellar," "8,172/3: hepatocellular carcinoma, scirrhous," "8,173/3: hepatocellular carcinoma, spindle cell variant," "8,174/3: hepatocellular carcinoma, clear cell type," or "8,175/3: hepatocellular carcinoma, pleomorphic type"; 2) the year at diagnosis from 2010 to 2015; and 3) the age at diagnosis older than 18 years. Individuals who had unclear TNM stage record, unknown survival time, missing cause of death, or unknown diagnostic confirmation were subsequently excluded. For further analysis, cases were grouped by the existence of lung metastasis ( Figure 1) .
We obtained the SEER data access permission before the project initiation. The study complied with the Declaration Figure 1 Flowchart of the enrolled patients in the study according to inclusion and exclusion criterion. Abbreviations: hCC, hepatocellular carcinoma; seeR, surveillance, epidemiology, and end Results. Variables definition and stratification 
Results
incidence of hCClM
Among finally enrolled 33,177 patients with HCC from 2010 to 2015, 2,084 patients were initially diagnosed with HCCLM with an incidence rate 6.28% ( Figure 1 ). No statistical significance could be found between different years. Only 44 (2.1%) individuals with HCCLM received surgery (including local tumor destruction), while remaining 97.8% patients treated conservatively (Table 1 ).
Risk factors for hCClM
As depicted in Figure 2A ). In addition, the homologous proportions of CSS were 65.2% vs 15.3%, 41.1% vs 5.7%, and 32.4% versus 2.4% ( Figure 2B ). Further, log-rank analysis revealed that age at diagnosis, gender, lymph node status, maximum primary tumor size, tumor differentiation, AFP level interpretation, and surgical intervention had impact on HCCLM cohort patients' OS with statistical significance (P<0.05, Figure 3 ). Besides factors above, bone metastasis was also associated with CSS in HCCLM cohort (P<0.05, Figure 4 ). Using the univariate and multivariate Cox regression model, age at diagnosis older than 40 years, unmarried status (HR: 1.134, 95% CI: 1.019-1.261, P=0.021), poor differentiation (HR: 1.732, 95% CI: 1.355-2.213, P<0.001) or undifferentiation (HR: 1.732, 95% CI: 1.355-2.213, P<0.001), and surgical intervention (including local tumor destruction and surgery) were identified as worse prognosis factors for OS (Table 2) . Similarly, these factors were also associated with a higher risk of mortality caused by cancer (Table 3) .
Discussion
HCCLM is a Gordian knot for clinicians because of its poor survival and limited effective treatment modalities. Previous articles mainly focused on the lung metastasis followed by primary liver tumor resection, while little is known about the simultaneous HCC and lung metastatic tumor. In the current Cancer specific survival rates study, the epidemiological result indicated that 6.28% patients with HCC presented with synchronous lung metastasis. Similarly, result from a Chinese cohort revealed that 39 of 862 (4.5%) HCC patients presented with initial lung metastasis. 13 However, a national follow-up survey of primary liver cancer in Japan showed that more than two-fifths of HCC patients developed pulmonary metastatic tumor. 14 The difference between our result and results from Japan study may be due to the discrepancy of enrolled patients. Our study only focused on the initial HCCLM cases, while Japan group analyzed all pulmonary metastatic cases during HCC progression. But, our result could be underestimated on account of the fact that asymptomatic HCCLM patients are unable to be detected. Strikingly, application of newly effective treatment modalities by clinicians may contribute to a slight increase in OS and CSS compared with data 3 years ago. chronal bone or brain metastasis, tumor poor pathological differentiation, and absence of surgery. This result suggested that clinicians should consider the possibility of lung metastasis when visiting HCC patients with above characteristics. Therefore, routine chest radiograph or low-dose computed tomography of lung was considered for these patients. Regrettably, other reported risk factors, such as microvascular invasion and tumor encapsulation, could not be assessed owing to no record in SEER. Survival estimates elucidated that age below 40 years, female, negative lymph node status, smaller tumor size, better tumor differentiation, normal AFP level, and surgery received may contribute to an optimistic survival. Prognostic factors for HCCLM were further investigated. The HCC patients with characteristics of age at diagnosis older than 40 years, unmarried status, tumor poor differentiation, and existence of surgery had a significantly higher risk of mortality. According to these recognized factors, clinicians could approximately assess the survival and prognosis of HCCLM patients.
Collectively, age at diagnosis, surgery for primary tumor, and tumor differential grade were crucial factors for both risk and prognosis prediction. Although HCC patients younger than 40 years had higher risk for lung metastasis, their OS and CSS appeared the best performance. The underlying causes perhaps were younger patients usually held more positive attitude toward treatment and had better physical status to tolerant various treatment modalities. In addition, the majority of patients did not receive surgery in this study, which most likely led to a lower survival rate compared with the reported data.
11 Consistent with previous reports, larger tumor size and positive AFP level predicted high risk for lung tumor colony formation. 4, 12 Notably, concomitant brain or bone metastasis had no impact on OS among HCCLM patients.
Limitations
First, only patients diagnosed after 2010 are enrolled for analysis because metastatic sites had been recorded until 2010. Second, inevitable bias exists because of absent details of tumor pathology and patient performance status. Third, SEER database represents merely US population, and other countries with high incidence of HCC were unable to be enrolled for global analysis. Last, the research is retrospective and the result still needs prospective trials to confirm a precise conclusion.
Conclusion
Generally, the incidence of initial pulmonary metastasis in HCC patients is 6.28% and the 5-year OS is still poor. Some clinicopathological features, such as age at diagnosis, tumor differential grade, and surgery for primary tumor, are highly predictive of HCCLM and significantly affect patients' survival. To our knowledge, the study is the first attempt to explore the epidemiological characteristics and identify the associated risk or prognostic factors of HCCLM using a population-based cancer registry database. The conclusion could be useful for a precise and individualized therapeutic schedule.
